Dermapharm Holding Se · XETR:DMP
Dermapharm — H1 2019 Earnings Presentation
16 slides from Dermapharm's earnings presentation, Sep 12, 2019
Slide 1: Investor and Analyst Conference Call H1 2019
Investor and Analyst Conference Call H1 2019 Grünwald, 12 September 2019
Slide 2: Agenda
Agenda 1. Overview 2. Financial figures H1 2019 3. Outlook FY 2019 4. Q&A
Slide 3: Agenda
Agenda 1. Overview 2. Financial figures H1 2019 3. Outlook FY 2019 4. Q&A
Slide 4: Dermapharm – Pharmaceutical excellence “Made in Germany”
Dermapharm – Pharmaceutical excellence “Made in Germany” Dermapharm’s integrated business model… …results in attractive financials… Group revenues H1 2019 in €m Total: 333.2 39.8 Herbal extracts Revenue split 118.4 175.0 Parallel import business Branded pharmaceuticals and other healthcare products
Slide 5: Dermapharm – Highlights H1 2019 (1/2)
Dermapharm – Highlights H1 2019 (1/2) Successful product development and expansion of facilities Pipeline of 50 ongoing development projects on track Update on Dekristol Mibe GmbH Arzneimittel: Construction of a new central logistics hub progressing as planned, completion expected until Septem
Slide 6: Dermapharm – Highlights H1 2019 (2/2)
Dermapharm – Highlights H1 2019 (2/2) Attractive M&A activities Successful integration of Strathmann and Trommsdorff New segment “Herbal Extracts” based on acquisition of Euromed FYTA – 20 % stake in producer of medical cannabis for pharmaceutical application Fitvia – 70 % stake in company s
Slide 7: Agenda
Agenda 1. Overview 2. Financial figures H1 2019 3. Outlook FY 2019 4. Q&A
Slide 8: Dermapharm Group Revenue – Growth in all segments
Dermapharm Group Revenue – Growth in all segments Dermapharm’s revenue development Dermapharm Group H1 2018 vs H1 2019 €m, YoY growth (%) Significant revenue growth of 18.9 % to € 333.2 million 333.2 Main growth drivers: +18.9% first-time consolidation of Euromed(2) as well as 39.8 organic g
Slide 9: Dermapharm Group EBITDA
Dermapharm Group EBITDA – Disproportional growth due to successful integration of the recent acquisition Dermapharm’s adjusted EBITDA(1) development Dermapharm Group H1 2018 vs H1 2019 €m, YoY growth (%) EBITDA up by 27.1 % to € 90.1 million (adjusted) and 21.6 % to € 81.6 million (unadjusted) EBI
Slide 10: Earnings before tax (EBT)
Earnings before tax (EBT) – Influenced by successful acquisitions and investments in future growth Dermapharm’s EBT(1) development Comments H1 2018 vs H1 2019 €m, YoY growth (%) EBT increased by 4.6 % to € 54.9 million (unadjusted) resulting in a lower margin of 16.5 % Group EBT 18.7% 16.5% Main
Slide 11: Cash flows and cash conversion
Cash flows and cash conversion – Reflecting strong dedication to future growth Cash flow and cash conversion(1) Comments in €m / in % of group EBITDA CF from operating activities mainly influenced by settlement of receivables from Themis Beteiligungs-AG in the first half of 2018 Cash 132.9% 49.3%
Slide 12: Balance sheet of Dermapharm Group
Balance sheet of Dermapharm Group Balance Sheet as of 30 June 2019 Comments in €m Total assets increased to € 960.6 million (31 December 2018: € 704.6 million) Non-current assets increased to € 657.9 million (31 December 2018: € 333.3 million) mainly due to an increase 960.6 960.6 in intangible
Slide 13: Agenda
Agenda 1. Overview 2. Financial figures H1 2019 3. Outlook FY 2019 4. Q&A
Slide 14: Growth strategy on track and conforming with guidance 2019
Growth strategy on track and conforming with guidance 2019 of the Annual Report 2018 Revenues ++14 % to +19 % 2019 vs. previous year (€572m) EBITDA 2019 +17 % to +22 % (adjusted) vs. previous year (€143.4m (adjusted)) “Growth rates are based on organic growth, new launches of in-house developments a
Slide 15: Investors’ and Analysts’ Conference Call Q&A
Investors’ and Analysts’ Conference Call H1 2019 Q&A
Slide 16: Investor contact
Investor contact Britta Hamberger Investor Relations Dermapharm Holding SE E-Mail: ir@dermapharm.com Phone: +49 (0) 89 641 86 233